United Pharmaceuticals (03933.HK): UBT48128 tablets have received clinical trial approval from the U.S. FDA.

Zhuhai Hengqin) Co., Ltd., a wholly-owned subsidiary of the company, has received approval from the U.S. Food and Drug Administration (FDA) for the clinical trial registration application (IND) of its self-developed Class 1 innovative drug UBT48128 tablets for the indications of overweight or obesity and type 2 diabetes. The IND numbers are 182060 and 182061, respectively.